Filing Details

Accession Number:
0001567619-20-020095
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-19 16:16:19
Reporting Period:
2020-11-17
Accepted Time:
2020-11-19 16:16:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1512762 Coherus Biosciences Inc. CHRS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1427569 Jean-Frederic Viret Coherus Biosciences, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City CA 94065
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.0001 Par Value Disposition 2020-11-17 1,995 $17.49 38,769 No 4 S Direct
Common Stock, $0.0001 Par Value Acquisiton 2020-11-17 1,500 $13.50 40,269 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-11-17 1,500 $0.00 1,500 $13.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
110,241 2024-11-05 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person.
  2. The transaction was executed in multiple trades in prices ranging from $17.27 to $17.85, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  3. Includes 31,250 restricted stock units.
  4. Includes 341 shares acquired on November 13, 2020, pursuant to Issuer's employee stock purchase plan.
  5. All of the shares underlying this option are vested and exercisable as of the date hereof.